CLINICAL_TRIALS
trial_result
· 2021-04-28
Clinical Trial Update: Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) [Phase 2]
Summary
Phase 2 trial update for pembrolizumab in esophageal squamous cell carcinoma after radical surgery with positive lymph nodes (KEYSTONE-004).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: ESCC, Adjuvant Treatment | Phase 2 | Status: UNKNOWN